PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE refer Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1	449A/PTO			Complete if Known	
INFORM	ATION DI	SCLOSURE	Application Number	10/790,562	
		PPLICANT	Filing Date	March 1, 2004	
JIAIDNE	ent bi A	di Dicarri	First Named Inventor	Hateboer et al. Bout	
			Group Art Unit	1636	
(use	zs many sheets as	necessary)	Examiner Name	W. Schlapkohl	
Sheet 1	of	1,	Attomey Docket Number	2578-4038 3115	

U.S. PATENT DOCUMENTS					
Examiner Cite Initials • No.1		Document Number	Publication Date	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevant
		Number - Kind Code <sup>2</sup> (if known)	MM-DD-YYYY	Cited Document	Passages or Relevant Figures Appear
WS	I	115-2 631,148	05 20 199T	Dolar et al.	duplicate
WS		US- 6,475,753	11-05-2002	Ruben et al.	
		US-			
-		US-			
		US-			
	T	US-			
		US-			
		US-	-		
	1	US-			
		US-	,		
	1	US-			
	1	US-			
	1	US-			
	1	US-			
	1	US-			
		US-			

Examiner Cite Initials* No.*	034	Foreign Patent Document	ment	Name of Patentee or	Pages, Columns, Lines,	
	Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>3</sup> (If known)	Publication Date MM-DD-YYYY	Applicant of Cited  Document	Where Relevant Passages or Relevant Figures Appear	Τ¢	
						-
		<del>                                     </del>	<del></del>		1	

Examiner Signature	Date Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>3</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO Complete if Known Application Number 10/790,562 INFORMATION DISCLOSURE Filing Date March 1, 2004 STATEMENT BY APPLICANT Bout Hateboer et al. First Named Inventor Group Art Unit 1636 (use as many sheets as necessary) W. Schlapkohl **Examiner Name** 2578-4038.3US Attorney Docket Number

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
WS		CARAVOKYRI et al., "Constitutive Episomal Expression of Polypeptide IX (pIX) in a 293-Based Cell Line Complements that Deficiency of pIX Mutant Adenovirus Type 5," Journal of Virology, November 1995, pp. 6627-6633, Vol. 69, No. 11.	
WS		YALLOP et al., "PER.C6® Cells for the Manufacture of Biopharmaceutical Proteins," Modern Biopharmaceuticals, ED. J. Knablein, 2005, WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany.	
		·	
-			
· · · · <u>· · · · · · · · · · · · · · · </u>		1	

Examiner Signature	Walter Schlapkohl 2006.09.06 14:00:09 -04'00'	Date Considered		
-----------------------	---	--------------------	--	--

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.